Cytokeratin 19 antibody

Catalog No. ABIN3026397

Product Details anti-Cytokeratin 19 Antibody

Target: Cytokeratin 19 (KRT19) (Keratin 19 (KRT19))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Cytokeratin 19 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Characteristics: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40 kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50 % -60 % of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Purification: Protein G affinity chromatography

Immunogen: Human breast cancer MCF-7 cells were used as the immunogen for this Cytokeratin 19 antibody.

Clone: A53-B-A2-26

Isotype: IgG2a kappa

Application Details

Application Notes: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Cytokeratin 19 antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate Buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. WB: 1-2 μg/mL,FACS: 0.5-1 μg/million cells,IF: 1-2 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the Cytokeratin 19 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for Cytokeratin 19

Target: Cytokeratin 19 (KRT19) (Keratin 19 (KRT19))

Alternative Name: Cytokeratin 19 (KRT19 Products)

Synonyms: CK19 antibody, K19 antibody, K1CS antibody, AI663979 antibody, EndoC antibody, Krt-1.19 antibody, Krt1-19 antibody, Ka19 antibody, k19 antibody, ck19 antibody, k1cs antibody, krt9 antibody, krt15 antibody, MGC76282 antibody, GK-19 antibody, MGC83069 antibody, KRT19 antibody, keratin 19 antibody, keratin 19 L homeolog antibody, keratin, type I cytoskeletal 19 antibody, KRT19 antibody, Krt19 antibody, krt19 antibody, krt19.L antibody, LOC100344434 antibody, LOC101117946 antibody

Background: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40  kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50 % -60 % of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Gene ID: 3880